MA40232A - Procédé de purification de la protéine de fusion tnfr:fc - Google Patents

Procédé de purification de la protéine de fusion tnfr:fc

Info

Publication number
MA40232A
MA40232A MA040232A MA40232A MA40232A MA 40232 A MA40232 A MA 40232A MA 040232 A MA040232 A MA 040232A MA 40232 A MA40232 A MA 40232A MA 40232 A MA40232 A MA 40232A
Authority
MA
Morocco
Prior art keywords
tnfr
fusion protein
purification
present
hcp
Prior art date
Application number
MA040232A
Other languages
English (en)
Inventor
Abir Banerjee
Chandranath Ganapathy
Ashok Mishra
Sorab Rustom Mody
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of MA40232A publication Critical patent/MA40232A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/12—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the preparation of the feed
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/20—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the sorbent material
    • B01D15/203—Equilibration or regeneration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/30—Partition chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3847—Multimodal interactions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424—Elution mode
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne la purification de la protéine de fusion tnfr:fc. L'invention concerne, plus précisément, un procédé de purification de la protéine de fusion tnfr:fc, caractérisé par une réduction du niveau des protéines des cellules hôtes (hcp). La présente invention concerne l'utilisation de la chromatographie en mode mixte et/ou de la chromatographie d'affinité pour produire une protéine de fusion tnfr:fc sensiblement exempte d'au moins l'une des enzymes de dégradation des protéines présentes dans les hcp.
MA040232A 2014-06-13 2015-06-13 Procédé de purification de la protéine de fusion tnfr:fc MA40232A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1919MU2014 2014-06-13

Publications (1)

Publication Number Publication Date
MA40232A true MA40232A (fr) 2017-04-19

Family

ID=53524922

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040232A MA40232A (fr) 2014-06-13 2015-06-13 Procédé de purification de la protéine de fusion tnfr:fc

Country Status (12)

Country Link
US (1) US10556942B2 (fr)
EP (1) EP3155009A1 (fr)
JP (1) JP6747985B2 (fr)
CN (1) CN106536565A (fr)
AU (1) AU2015273049B2 (fr)
BR (1) BR112016029157A8 (fr)
CA (1) CA2951766A1 (fr)
MA (1) MA40232A (fr)
MX (1) MX2016016318A (fr)
PH (1) PH12016502482A1 (fr)
RU (1) RU2698654C2 (fr)
WO (1) WO2015189832A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
KR20170138426A (ko) * 2015-03-13 2017-12-15 삼성바이오에피스 주식회사 항-tnf-알파 폴리펩티드 조성물 및 그 용도
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
CN109311948B (zh) 2016-05-11 2022-09-16 思拓凡生物工艺研发有限公司 清洁和/或消毒分离基质的方法
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
JP7031934B2 (ja) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックス
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
EP3455243B1 (fr) 2016-05-11 2021-03-24 Cytiva BioProcess R&D AB Matrice de séparation
EP3455240B1 (fr) 2016-05-11 2025-01-01 Cytiva BioProcess R&D AB Procédé de conservation d'une matrice de séparation
US12448411B2 (en) 2016-09-30 2025-10-21 Cytiva Bioprocess R&D Ab Separation method
MY199833A (en) * 2017-08-17 2023-11-24 Just Evotec Biologics Inc Method of purifying glycosylated protein from host cell galectins and other contaminants
CA3072129A1 (fr) * 2017-08-30 2019-03-07 Ares Trading S.A. Procede de purification de proteines
US11952399B2 (en) * 2018-12-18 2024-04-09 Amgen Inc. Methods for purifying proteins
EP3917951A1 (fr) * 2019-01-30 2021-12-08 Amgen, Inc Attributs de l'aflibercept et leurs procédés de caractérisation et de modification
KR102286892B1 (ko) * 2019-07-08 2021-08-06 삼천당제약주식회사 안과용 단백질 제제의 정제방법
CN112876567A (zh) * 2019-11-29 2021-06-01 广东菲鹏制药股份有限公司 Fc融合蛋白及其纯化方法
US20230357315A1 (en) * 2020-03-11 2023-11-09 Dr. Reddy's Laboratories Limited METHOD OF PURIFYING AN Fc-FUSION PROTEIN
CN113563469A (zh) * 2020-04-28 2021-10-29 江苏中新医药有限公司 高回收率纯化阿达木单抗的方法
WO2022234412A1 (fr) * 2021-05-03 2022-11-10 Lupin Limited Procédé de purification de protéines de fusion fc
EP4408857A4 (fr) * 2021-09-28 2025-11-05 Kashiv Biosciences Llc Procédé amélioré de purification de protéine de fusion
EP4408879A4 (fr) * 2021-09-28 2025-08-27 Kashiv Biosciences Llc Procédé amélioré de purification de protéine de fusion
EP4408856A4 (fr) * 2021-09-28 2025-11-12 Kashiv Biosciences Llc Procédé amélioré pour purification de protéine
CN118414350A (zh) * 2021-10-19 2024-07-30 阿特根公司 纯化具有igg fc结构域的融合蛋白的方法
US20250026784A1 (en) * 2021-11-29 2025-01-23 Tosoh Corporation Separation method of antibody
CN119060168A (zh) * 2024-09-26 2024-12-03 广东丸美生物技术股份有限公司 一种具有低电导率的重组胶原蛋白溶液及其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2021284C1 (ru) * 1991-05-30 1994-10-15 Всесоюзный научно-исследовательский институт технологии кровезаменителей и гормональных препаратов Способ очистки клинических фракций декстрана
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
EP1478394B1 (fr) 2002-02-27 2008-07-30 Immunex Corporation Composition stabilisée comprenant TNFR-Fc et arginine
DK1601697T3 (da) 2003-02-28 2007-10-01 Lonza Biologics Plc Oprensning af antistof ved protein A- og ionbytningskromatografi
WO2007109163A2 (fr) * 2006-03-16 2007-09-27 Amgen Inc Tampon de lavage et procédé d'utilisation correspondant
JP2010501623A (ja) * 2006-08-28 2010-01-21 アレス トレーディング ソシエテ アノニム Ｆｃ含有タンパク質の精製法
JP2010501622A (ja) * 2006-08-28 2010-01-21 アレス トレーディング ソシエテ アノニム Ｆｃ−融合タンパク質の精製法
JP2011500757A (ja) * 2007-10-22 2011-01-06 メルク セローノ ソシエテ アノニム Ｆｃ含有タンパク質の精製方法
JP2011514895A (ja) * 2008-02-29 2011-05-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド 精製免疫グロブリン融合タンパク質およびその精製方法
WO2010056550A1 (fr) 2008-10-29 2010-05-20 Wyeth Llc Procédés de purification de molécules de liaison d’antigène monodomaines
CN102712673B (zh) * 2010-01-22 2014-04-30 贝林格尔.英格海姆国际有限公司 用于纯化含fc的蛋白的色谱方法
WO2012176158A1 (fr) 2011-06-24 2012-12-27 Dr. Reddy's Laboratories Limited Purification de protéine chimérique
BR112014000352A2 (pt) * 2011-07-08 2017-02-14 Merck Sharp & Dohe Corp método de purificar uma proteína de fusão-fc, proteínas de fusão contendo fc purificada, tnfr:fc purificada, e tnfr:fc elevadamente purificada
EP2753634B1 (fr) * 2011-08-17 2017-11-01 Ares Trading S.A. Procédé de préparation d'une forme active de la protéine de fusion tnfr-fc
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
PE20150996A1 (es) * 2012-09-11 2015-08-01 Coherus Biosciences Inc Etanercept correctamente plegado de alta pureza y excelente rendimiento
CN102911250B (zh) * 2012-09-29 2014-04-16 浙江海正药业股份有限公司 酸性重组蛋白药物的纯化方法
US9649383B2 (en) * 2012-11-19 2017-05-16 Merck Sharp & Dohme Corp. Liquid formulations for TNFR:Fc fusion proteins
LT2969099T (lt) * 2013-03-14 2018-09-10 Amgen Inc. Pratekėjusio ligando pašalinimas afininiame gryninime
US8946395B1 (en) * 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography

Also Published As

Publication number Publication date
CN106536565A (zh) 2017-03-22
RU2698654C2 (ru) 2019-08-28
EP3155009A1 (fr) 2017-04-19
US20170152298A1 (en) 2017-06-01
AU2015273049B2 (en) 2019-11-14
BR112016029157A2 (pt) 2017-08-22
RU2017100005A (ru) 2018-07-13
JP6747985B2 (ja) 2020-08-26
MX2016016318A (es) 2017-06-12
CA2951766A1 (fr) 2015-12-17
US10556942B2 (en) 2020-02-11
JP2017521389A (ja) 2017-08-03
AU2015273049A1 (en) 2017-01-12
PH12016502482A1 (en) 2017-04-10
BR112016029157A8 (pt) 2021-07-06
WO2015189832A1 (fr) 2015-12-17
RU2017100005A3 (fr) 2019-02-28

Similar Documents

Publication Publication Date Title
PH12016502482A1 (en) Process for the purification of tnfr:fc fusion protein
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
MX2023008559A (es) Proteínas de fusión fc heterodiméricas il15/il15ra.
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
EP4299595A3 (fr) Compositions et procédés se rapportant à des constructions fc génétiquement modifiées
AU2018333114A1 (en) New use for treatment of Clostridium difficile infections
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
MX2020009461A (es) Anticuerpos anti-proteína que contiene dominio de inmunologlubina rfig elacionado con el receptor de poliovirus (pvrig) y métodos de uso.
PH12020550927A1 (en) Therapeutic enzyme fusion protein having novel structure and use thereof
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
MX384346B (es) Bloqueo de cd73.
MX358137B (es) Composiciones del polipéptido de fusión tnfr: fc exentas de arginina y métodos de uso.
MX391632B (es) Proteasa de cisteína.
ZA201705113B (en) Cysteine protease
MX375524B (es) Anticuerpos anti-axl.
SG10201902924RA (en) Antibodies that bind ebola glycoprotein and uses thereof
HK1246304A1 (zh) 包含抗cd73抗体和a2a受体抑制剂的治疗组合及其用途
SG10201907582WA (en) Bicyclic heterocycles as fgfr4 inhibitors
NZ749279A (en) Compositions and methods related to engineered fc constructs
MX2018009266A (es) Conjugado de enzimas terapeuticas.
WO2016061389A3 (fr) Anticorps anti-alpha-synucléine et leurs méthodes d'utilisation
WO2017015622A3 (fr) Protéines de liaison à gdf11 et leurs utilisations
IN2014DN08721A (fr)
AU2017317563A8 (en) Detergent compositions comprising xanthan lyase variants I
PH12020500054A1 (en) Novel therapeutic enzyme fusion protein and use thereof